Skip to content

Clinical Efficacy Observation of Detoxification and Anti-swelling Formula Topical Application with Hugging Method Based on Hugging and Protecting the Lesion Area Theory for Perianal Abscess in Leukemia Patients during Chemotherapy-induced Ulcerative Stage:A randomized controlled

Clinical Efficacy Observation of Detoxification and Anti-swelling Formula Topical Application with Hugging Method Based on Hugging and Protecting the Lesion Area Theory for Perianal Abscess in Leukemia Patients during Chemotherapy-induced Ulcerative Stage

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000598
Enrollment
Unknown
Registered
2026-03-18
Start date
2026-03-31
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute leukemia

Interventions

Experimental Group:Experimental group: When using, take 1 packet of detoxifying and anti-inflammatory decoction, pour it into a disposable medicine bowl, and place two pieces of sterile gauze immersed
Control Group:Pour 60ml of Recovery Xin solution into the medication bowl, with the rest of the procedure being the same as the experimental group.

Sponsors

Hangzhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Age=18 years 2.Patients who meet the above diagnostic criteria for acute leukemia 3.Who meet the above clinical criteria for anal abscess in traditional Chinese and Western medicine 4.Patients with anal abscess in the stage of abscess formation who have not received other treatments 5.Patients who voluntarily agree to participate in this trial and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Patients with concomitant ulcerative colitis, rectal tumors, or other perianal diseases; 2. Patients with a history of perianal abscess surgery; 3. Patients with severe cardiovascular diseases or mental disorders; 4. Patients with obvious allergic constitutions or a clear history of skin allergies; 5. Pregnant or breastfeeding women; 6. Patients currently participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
TCM Syndrome Score;

Secondary

MeasureTime frame
Treatment effect;Anal pain level;Inflammatory Factors;

Countries

China

Contacts

Public ContactShan Liming

Hangzhou First People's Hospital

shanlm0818@163.com13857120696

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026